Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Spyre Therapeutics ( (SYRE) ) is now available.
On November 4, 2025, Spyre Therapeutics announced positive interim Phase 1 results for SPY003, an investigational monoclonal antibody targeting IL-23, showing it was well-tolerated with an 85-day half-life, supporting potential quarterly or twice-yearly dosing. The company also reported financial results for the third quarter of 2025, highlighting a strengthened balance sheet with $783 million in cash and marketable securities, and ongoing Phase 2 trials for multiple investigational antibodies, positioning Spyre for significant developments in 2026.
The most recent analyst rating on (SYRE) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
Spyre Therapeutics is facing significant financial challenges with consistent revenue and profitability issues. Its strong equity position is overshadowed by operational cash flow problems and persistent losses. Technically, the stock is under bearish pressure, and the valuation is complicated by a negative P/E ratio and lack of dividends. These factors combined result in a low overall stock score, reflecting the high-risk nature of investing in this biotechnology company.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. The company targets validated mechanisms for safe and effective treatment of conditions such as ulcerative colitis, Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, aiming to offer infrequent dosing options.
Average Trading Volume: 813,760
Technical Sentiment Signal: Hold
Current Market Cap: $1.84B
Find detailed analytics on SYRE stock on TipRanks’ Stock Analysis page.